JPWO2021165992A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021165992A5 JPWO2021165992A5 JP2022550009A JP2022550009A JPWO2021165992A5 JP WO2021165992 A5 JPWO2021165992 A5 JP WO2021165992A5 JP 2022550009 A JP2022550009 A JP 2022550009A JP 2022550009 A JP2022550009 A JP 2022550009A JP WO2021165992 A5 JPWO2021165992 A5 JP WO2021165992A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- therapeutic agent
- gating
- composition according
- cannabidiol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 30
- 239000003814 drug Substances 0.000 claims 16
- 229940124597 therapeutic agent Drugs 0.000 claims 13
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims 8
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims 8
- 229950011318 cannabidiol Drugs 0.000 claims 8
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims 8
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims 8
- 208000019622 heart disease Diseases 0.000 claims 8
- 208000020446 Cardiac disease Diseases 0.000 claims 7
- 206010003119 arrhythmia Diseases 0.000 claims 6
- 230000006793 arrhythmia Effects 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 206010061218 Inflammation Diseases 0.000 claims 5
- 230000004054 inflammatory process Effects 0.000 claims 5
- 206010019280 Heart failures Diseases 0.000 claims 4
- 101000694017 Homo sapiens Sodium channel protein type 5 subunit alpha Proteins 0.000 claims 4
- 230000002411 adverse Effects 0.000 claims 4
- 230000000302 ischemic effect Effects 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 230000000747 cardiac effect Effects 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 230000001771 impaired effect Effects 0.000 claims 3
- 208000010125 myocardial infarction Diseases 0.000 claims 3
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 claims 2
- YSIBYEBNVMDAPN-CMDGGOBGSA-N (e)-4-oxo-4-(3-triethoxysilylpropylamino)but-2-enoic acid Chemical compound CCO[Si](OCC)(OCC)CCCNC(=O)\C=C\C(O)=O YSIBYEBNVMDAPN-CMDGGOBGSA-N 0.000 claims 2
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 claims 2
- 206010002383 Angina Pectoris Diseases 0.000 claims 2
- 108010019625 Atazanavir Sulfate Proteins 0.000 claims 2
- 229940022962 COVID-19 vaccine Drugs 0.000 claims 2
- 208000031229 Cardiomyopathies Diseases 0.000 claims 2
- 101000693993 Homo sapiens Sodium channel protein type 4 subunit alpha Proteins 0.000 claims 2
- 206010021143 Hypoxia Diseases 0.000 claims 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 2
- 206010054880 Vascular insufficiency Diseases 0.000 claims 2
- 230000036982 action potential Effects 0.000 claims 2
- 230000006978 adaptation Effects 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 2
- 229960003796 atazanavir sulfate Drugs 0.000 claims 2
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims 2
- 229960004099 azithromycin Drugs 0.000 claims 2
- 229960003677 chloroquine Drugs 0.000 claims 2
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 claims 2
- 230000003111 delayed effect Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 claims 2
- 229960004171 hydroxychloroquine Drugs 0.000 claims 2
- 230000003345 hyperglycaemic effect Effects 0.000 claims 2
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 claims 2
- 230000001146 hypoxic effect Effects 0.000 claims 2
- 230000000642 iatrogenic effect Effects 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 208000004731 long QT syndrome Diseases 0.000 claims 2
- 229960001797 methadone Drugs 0.000 claims 2
- 230000003680 myocardial damage Effects 0.000 claims 2
- 208000031225 myocardial ischemia Diseases 0.000 claims 2
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 claims 2
- 229960002194 oseltamivir phosphate Drugs 0.000 claims 2
- 230000002085 persistent effect Effects 0.000 claims 2
- 230000002035 prolonged effect Effects 0.000 claims 2
- 238000007634 remodeling Methods 0.000 claims 2
- 229960000329 ribavirin Drugs 0.000 claims 2
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 2
- 208000013363 skeletal muscle disease Diseases 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- 208000019553 vascular disease Diseases 0.000 claims 2
- 208000023577 vascular insufficiency disease Diseases 0.000 claims 2
- 208000025721 COVID-19 Diseases 0.000 claims 1
- 241000237858 Gastropoda Species 0.000 claims 1
- 208000023178 Musculoskeletal disease Diseases 0.000 claims 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000011324 bead Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 230000002779 inactivation Effects 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 230000004792 oxidative damage Effects 0.000 claims 1
- 230000036542 oxidative stress Effects 0.000 claims 1
- 239000008188 pellet Substances 0.000 claims 1
- 230000003239 periodontal effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000011148 porous material Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 230000006950 reactive oxygen species formation Effects 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202021007184 | 2020-02-19 | ||
| IN202021007184 | 2020-02-19 | ||
| IN202021013770 | 2020-03-29 | ||
| IN202021013770 | 2020-03-29 | ||
| PCT/IN2021/050159 WO2021165992A1 (en) | 2020-02-19 | 2021-02-19 | Compositions and therapeutic uses of cannabidiol |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023516284A JP2023516284A (ja) | 2023-04-19 |
| JPWO2021165992A5 true JPWO2021165992A5 (https=) | 2024-07-09 |
| JP2023516284A5 JP2023516284A5 (https=) | 2024-07-09 |
Family
ID=77391770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022550009A Pending JP2023516284A (ja) | 2020-02-19 | 2021-02-19 | カンナビジオールの組成物および治療的使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230123654A1 (https=) |
| EP (1) | EP4106870A4 (https=) |
| JP (1) | JP2023516284A (https=) |
| CN (1) | CN115916336A (https=) |
| AU (1) | AU2021223191A1 (https=) |
| CA (1) | CA3171890A1 (https=) |
| IL (1) | IL295753A (https=) |
| WO (1) | WO2021165992A1 (https=) |
| ZA (1) | ZA202210355B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL296892A (en) * | 2020-03-29 | 2022-12-01 | Akseera Pharma Corp | Interaction of sars-cov-2 proteins through a molecular or cellular mechanism of host cells and compounds for the treatment of covid -19 |
| AU2021250462A1 (en) * | 2020-04-02 | 2022-12-01 | Incannex Healthcare Limited | Methods and compositions for treating or preventing an inflammatory condition |
| WO2022122904A1 (en) * | 2020-12-09 | 2022-06-16 | Chanelle Mccoy Cbd Limited | A delayed-release capsule of cannabidiol |
| AU2022204290A1 (en) * | 2020-12-12 | 2023-07-27 | Akseera Pharma Corp. | Cannabidiol for augmenting vaccine mediated immunity and prophylaxis of covid-19 |
| IL309886A (en) * | 2021-07-15 | 2024-03-01 | Incannex Healthcare Ltd | A preparation containing cannabidiol and hydroxychloroquine in a combined capsule at a fixed dose |
| JPWO2024043242A1 (https=) * | 2022-08-23 | 2024-02-29 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7087374B2 (en) * | 2003-06-26 | 2006-08-08 | The Research Foundation Of State University Of New York | Screen for sodium channel modulators |
| MX376077B (es) * | 2013-03-13 | 2025-03-07 | Univ Cincinnati | Tratamiento de una disfuncion cardiaca diastolica con un agonista del receptor trpv2. |
| WO2016161138A1 (en) * | 2015-03-31 | 2016-10-06 | Stamets Paul Edward | Antiviral activity from medicinal mushrooms and their active constituents |
| LT6486B (lt) * | 2016-04-13 | 2018-01-10 | UAB "SatiMed" | Aliejinio gelio kompozicija su aktyviausiais junginiais iš c. sativa ir m. arvensis ir jos pateikimo sistema, skirta giliųjų audinių uždegimo ir skausmo mažinimui |
| IL262713B2 (en) * | 2016-05-02 | 2024-07-01 | Stero Biotechs Ltd | Cannabidiol for reducing a steroid dose and treating inflammatory and autoimmune diseases |
| CN108079305A (zh) * | 2016-11-23 | 2018-05-29 | 汉义生物科技（北京）有限公司 | 大麻二酚与三环类抗抑郁药的药物组合物及其用途 |
| AU2018273410A1 (en) * | 2017-05-26 | 2020-01-16 | Altum Pharmaceuticals Inc. | Biphasix cannabinoid delivery |
| US20210085801A1 (en) * | 2017-12-12 | 2021-03-25 | Cardiol Therapeutics Inc. | Amphiphilic block copolymers, micelles, and methods for treating or preventing heart failure |
| KR102632946B1 (ko) * | 2018-01-13 | 2024-02-05 | 트루티바 인코포레이티드 | 노화 방지 및 피부 톤 미백 조성물 및 이를 위한 방법 |
| CN110575448A (zh) * | 2018-06-08 | 2019-12-17 | 云南汉素生物科技有限公司 | 大麻二酚组合物及其用途 |
| WO2020183456A1 (en) * | 2019-03-10 | 2020-09-17 | Bol Pharma Ltd. | Cannabinoid combinations for treating chronic pain in dialysis patients |
-
2021
- 2021-02-19 JP JP2022550009A patent/JP2023516284A/ja active Pending
- 2021-02-19 EP EP21756726.2A patent/EP4106870A4/en not_active Withdrawn
- 2021-02-19 CN CN202180029644.1A patent/CN115916336A/zh active Pending
- 2021-02-19 CA CA3171890A patent/CA3171890A1/en active Pending
- 2021-02-19 US US17/800,563 patent/US20230123654A1/en not_active Abandoned
- 2021-02-19 WO PCT/IN2021/050159 patent/WO2021165992A1/en not_active Ceased
- 2021-02-19 AU AU2021223191A patent/AU2021223191A1/en active Pending
- 2021-02-19 IL IL295753A patent/IL295753A/en unknown
-
2022
- 2022-09-19 ZA ZA2022/10355A patent/ZA202210355B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Keane et al. | Chronic ectopic tachycardia of infancy and childhood | |
| Buckley et al. | Diltiazem: a reappraisal of its pharmacological properties and therapeutic use | |
| Graboys et al. | Efficacy of amiodarone for refractory supraventricular tachyarrhythmias | |
| Boriani et al. | Pharmacological cardioversion of atrial fibrillation: current management and treatment options | |
| Heng et al. | Effects of intravenous verapamil on cardiac arrhythmias and on the electrocardiogram | |
| Singh | Amiodarone: historical development and pharmacologic profile | |
| Capucci et al. | Safety of oral propafenone in the conversion of recent onset atrial fibrillation to sinus rhythm:: A prospective parallel placebo-controlled multicentre study | |
| Brubaker et al. | Alternative treatment options for atrioventricular-nodal-reentry tachycardia: an emergency medicine review | |
| Williams et al. | Current and emerging antiarrhythmic drug therapy for ventricular tachycardia | |
| US20110230552A1 (en) | Use of dronedarone for the preparation of a medicament for the prevention of stroke or transient ischemic attack | |
| JPWO2021165992A5 (https=) | ||
| US20110166221A1 (en) | Use of dronedarone for the preparation of a medicament for use in the prevention of cardioversion | |
| Zipes et al. | Studies with aprindine | |
| Amino et al. | Comparative study of nifekalant versus amiodarone for shock-resistant ventricular fibrillation in out-of-hospital cardiopulmonary arrest patients | |
| Schumacher et al. | Effect of oxygen and acetazolamide on nocturnal cardiac conduction, repolarization, and arrhythmias in precapillary pulmonary hypertension and sleep-disturbed breathing | |
| Chukwunyere et al. | COVID-19-related arrhythmias and the possible effects of ranolazine | |
| Geller et al. | Efficacy and safety of moricizine in the maintenance of sinus rhythm in patients with recurrent atrial fibrillation | |
| Shiga et al. | Clinical outcome in patients with paroxysmal or persistent atrial fibrillation receiving bepridil | |
| Rao | Coronavirus Disease (Covid-19): A Disease of the Vascular Endothelium | |
| Cardoso et al. | Inhalatory pentamidine therapy and the duration of the QT interval in HIV-infected patients | |
| Aronow | Drug treatment of elderly patients with acute myocardial infarction: practical recommendations | |
| Foster et al. | Use of verapamil to control an inappropriate chronic sinus tachycardia | |
| Kostis et al. | Acute myocardial infarction caused by multivessel coronary spasm due to calcium channel blocker withdrawal | |
| Palimonka et al. | Antazoline renaissance in the treatment of cardiac arrhythmia: A review | |
| Schellack et al. | Understanding anticoagulation therapy for stroke prevention and atrial fibrillation |